OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Danilov on the Future of BTK Inhibitors in CLL

August 10th 2022

Alexey V. Danilov, MD, PhD, discusses the future of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Beckermann on the Need for Biomarkers in Frontline RCC

August 10th 2022

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Dr. Hamilton on Tests to Identify HER2-Low and HER2+ Breast Cancer

August 10th 2022

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Dr. Sheffield on the Economic Cost of Delaying of Treatment in NSCLC

August 9th 2022

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Dr. Levy on the Efficacy of Datopotamab Deruxtecan Plus Pembrolizumab in NSCLC

August 9th 2022

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Dr. Spira on the Further Investigations of Lazertinib/Amivantamab in EGFR-Mutant NSCLC

August 8th 2022

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Dr. Marmarelis on the Efficacy of Lazertinib/Amivantamab Plus Chemotherapy in EGFR-Mutated NSCLC

August 8th 2022

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer

August 8th 2022

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.

Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL

August 8th 2022

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC

August 7th 2022

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

Dr. Iams on the Evaluation of Sotorasib in KRAS G12C–Mutant Solid Tumors

August 7th 2022

Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

August 5th 2022

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

August 5th 2022

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma

August 4th 2022

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

August 4th 2022

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

Dr. Ready on Leveraging Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

August 3rd 2022

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

August 3rd 2022

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

August 3rd 2022

Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Spira on the Evaluation of Tusamitamab Ravtansine Plus Pembrolizumab in NSCLC

August 3rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.